Article info
PDFClinical science
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes
- Correspondence to Dr Arun Singh, Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH 44106, USA; singha{at}ccf.org
Citation
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes
Publication history
- Received April 22, 2019
- Revised July 3, 2019
- Accepted July 6, 2019
- First published August 1, 2019.
Online issue publication
March 24, 2020
Article Versions
- Previous version (24 March 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.